SEC 13F Intelligence

Managers / Q3 2020 · view latest →

Healthcare Value Capital, LLC

CIK 0001458461 · 50 TICE BLVD, SUITE 140, WOODCLIFF LAKE, NJ, 07677 · 212-488-5411

Reported Value
$30M
Q3 2020
Positions
18
Filings on Record
11
2019–present window
Filed
Nov 16, 2020
original filing

Summary

Healthcare Value Capital, LLC reported $30M in U.S.-listed holdings across 18 positions for Q3 2020.

Its largest position, Glaxosmithkline, represents 12.4% of the portfolio.

Compared with Q2 2020, the fund opened 5 new positions and exited 5.

Portfolio Metrics

Turnover
+20.8%
vs prior filed quarter
Top-10 Concentration
+82.9%
share of reported value
Largest Position
+12.4%
Glaxosmithkline
New / Exited
5 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $26MQ1 ’19Q2 ’19: $53MQ3 ’19: $55MQ3 ’19Q4 ’19: $34MQ1 ’20: $59MQ1 ’20Q2 ’20: $39MQ3 ’20: $30MQ3 ’20Q4 ’20: $30MQ1 ’21: $45MQ1 ’21Q2 ’21: $50MQ3 ’21: $51MQ3 ’21filingsflow.com

Portfolio Composition

By security type
Common Stock: 72.6%Other: 25.7%ETP: 1.7%
  • Common Stock · 72.6% · $22M
  • Other · 25.7% · $8M
  • ETP · 1.7% · $510,000

Quarter-over-Quarter Changes full breakdown →

vs Q2 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VYNE THERAPEUTICS INCNEW+1.80M1.80M+$3M$3M
MRNAMODERNA INCNEW+10.0K10.0K+$708,000$708,000
NVAXNOVAVAX INCNEW+5.0K5.0K+$542,000$542,000
PROSHARES TR IINEW+25.0K25.0K+$510,000$510,000
ADAMAS PHARMACEUTICALS INCNEW+100.0K100.0K+$412,000$412,000
MENLO THERAPEUTICS INCSOLD OUT−1.70M0−$3M$0
WBAWALGREENS BOOTS ALLIANCE INCSOLD OUT−50.0K0−$2M$0
CVSCVS HEALTH CORPSOLD OUT−25.0K0−$2M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2020

13 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1GLAXOSMITHKLINE PLCSPONSORED ADR12.40%$4M100.0K
2JAZZJAZZ PHARMACEUTICALS PLChistory →SHS USD11.75%$4M25.0K
3GILDGILEAD SCIENCES INChistory →COM10.41%$3M50.0K
4ABBVABBVIE INChistory →COM10.10%$3M35.0K
5VYNE THERAPEUTICS INCCOM NEW9.85%$3M1.80M
6PROSHARES TRULTRAPRO SHORT S7.17%$2M250.0K
7TYME TECHNOLOGIES INCCOM7.03%$2M2.17M
8MCKMCKESSON CORPhistory →COM4.91%$1M10.0K
9CLOVIS ONCOLOGY INCCOM4.80%$1M250.0K
10ANTARES PHARMA INCCOM4.45%$1M500.0K
11CAHCARDINAL HEALTH INChistory →COM3.87%$1M25.0K
12GREENLANE HLDGS INCCL A1.85%$560,000250.0K
13ADAMAS PHARMACEUTICALS INCCOM1.36%$412,000100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2021$51M25Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$50M23Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$45M22May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$30M17Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$30M18Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$39M19Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$59M26May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$34M16Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$55M22Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$53M19Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$26M10May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.